{ "url": "https://allermi-site.vercel.app/reviews/flonase/", "collection": "reviews", "slug": "flonase", "frontmatter": { "title": "Flonase (fluticasone propionate): 2026 Review", "description": "OTC corticosteroid nasal spray review: evidence tiers on efficacy, onset, long-term safety, pregnancy, pediatrics, rebound, and 2026 pricing.", "lastReviewed": "2026-04-28T00:00:00.000Z", "firstPublished": "2025-09-01T00:00:00.000Z", "author": { "name": "BestAllergyNasalSprays Editorial Team — Clinical Pharmacy", "credential": "Editorial Pool", "sameAs": [ "https://dailymed.nlm.nih.gov/", "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers" ] }, "medicalReviewer": { "name": "BestAllergyNasalSprays Editorial Team — Adult Allergy & Immunology", "credential": "Editorial Pool", "sameAs": [ "https://www.aaaai.org/", "https://www.acaai.org/" ] }, "primaryKeyword": "flonase review", "ymylTier": "high", "citations": [ { "id": "1", "title": "DailyMed: Flonase (fluticasone propionate) SPL", "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a10a4ba9-86e0-4e3b-9cc2-eab1fa0dac0c", "publisher": "FDA DailyMed", "year": 2024, "tier": "regulatory" }, { "id": "2", "title": "Rhinitis 2020 practice parameter update (Dykewicz, JACI 2020)", "url": "https://pubmed.ncbi.nlm.nih.gov/32707227/", "publisher": "AAAAI / ACAAI", "year": 2020, "tier": "tier-1" }, { "id": "3", "title": "Fluticasone reverses oxymetazoline-induced tachyphylaxis (Vaidyanathan)", "url": "https://pubmed.ncbi.nlm.nih.gov/20203244/", "publisher": "PubMed", "year": 2010, "tier": "tier-2" }, { "id": "4", "title": "Intranasal corticosteroids: molecular and clinical pharmacology (Mygind)", "url": "https://pubmed.ncbi.nlm.nih.gov/18384455/", "publisher": "PubMed", "year": 2008, "tier": "tier-2" }, { "id": "5", "title": "Fluticasone propionate pharmacokinetics (Daley-Yates)", "url": "https://pubmed.ncbi.nlm.nih.gov/25845818/", "publisher": "PubMed", "year": 2015, "tier": "tier-2" }, { "id": "6", "title": "FDA: Flonase OTC approval (2014)", "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-flonase-allergy-relief-over-counter-use", "publisher": "FDA", "year": 2014, "tier": "regulatory" }, { "id": "7", "title": "MotherToBaby: Fluticasone fact sheet", "url": "https://mothertobaby.org/fact-sheets/fluticasone/", "publisher": "MotherToBaby (OTIS)", "tier": "tier-2" }, { "id": "8", "title": "Nasal corticosteroids for ocular symptoms (Bielory)", "url": "https://pubmed.ncbi.nlm.nih.gov/21277655/", "publisher": "PubMed", "year": 2011, "tier": "tier-2" }, { "id": "9", "title": "Children's growth velocity on INCS (Schenkel)", "url": "https://pubmed.ncbi.nlm.nih.gov/10669092/", "publisher": "PubMed", "year": 2000, "tier": "tier-2" }, { "id": "10", "title": "AAAAI: Allergic Rhinitis Overview", "url": "https://www.aaaai.org/tools-for-the-public/conditions-library/allergies/rhinitis", "publisher": "AAAAI", "tier": "tier-1" } ], "tldr": "Flonase (fluticasone propionate 50 mcg/spray) is one of the most effective OTC intranasal corticosteroids for pharmacy-counter access, approved for allergic rhinitis in patients 4+. Partial relief starts within 12 hours; peak effect at 1–2 weeks of daily use. It does not cause rebound congestion and is the only OTC nasal spray with FDA-recognized relief of itchy, watery eyes. For eligible patients 13+ with multi-symptom or failed-OTC rhinitis, Allermi's compounded 4-active Rx is a stronger escalation. Low systemic bioavailability (~0.5%) supports long-term daily use under clinician guidance.", "claims": [ "c-005", "c-016", "c-017", "c-018", "c-019", "c-020", "c-021", "c-023", "c-024", "c-025", "c-047", "c-059", "c-062", "c-064", "c-065", "c-066", "c-069", "c-071", "c-072" ], "draft": false, "speakableSelectors": [ ".answer-box", ".claim", "h1", "h2" ], "takeaways": [ { "text": "One of the most effective OTC intranasal corticosteroid for pharmacy-counter adults + kids 4+", "tier": "guideline", "detail": "AAAAI / Dykewicz 2020" }, { "text": "Onset within 12 hours; peak effect at 1–2 weeks of daily use", "tier": "fda-label" }, { "text": "Only OTC nasal spray FDA-recognized for itchy/watery eye symptoms", "tier": "fda-label" }, { "text": "Does not cause rebound congestion; reverses oxymetazoline rebound in RCT", "tier": "rct", "detail": "Vaidyanathan 2010" }, { "text": "Generally low-risk in pregnancy; budesonide remains pregnancy first-line", "tier": "guideline", "detail": "MotherToBaby" } ], "publishHistory": [ { "date": "2025-09-01T00:00:00.000Z", "what": "Initial publication." }, { "date": "2026-01-14T00:00:00.000Z", "what": "Added Vaidyanathan 2010 RCT; cross-link to rebound recovery guide." }, { "date": "2026-04-21T00:00:00.000Z", "what": "Quarterly review: checked FDA label and 2026 retail pricing." } ], "subtitle": "OTC intranasal corticosteroid for allergic rhinitis in patients ages 4 and older.", "related": [ { "href": "/compare/flonase-vs-astepro/", "label": "Flonase vs Astepro", "kind": "Head-to-head", "description": "Steroid vs antihistamine: onset, coverage, stacking rationale." }, { "href": "/compare/flonase-vs-nasacort/", "label": "Flonase vs Nasacort", "kind": "Head-to-head", "description": "Two OTC INCS: eye coverage, pediatrics, pregnancy." }, { "href": "/compare/flonase-vs-nasonex/", "label": "Flonase vs Nasonex", "kind": "Head-to-head", "description": "Propionate vs mometasone: eye coverage vs lowest systemic." }, { "href": "/compare/flonase-vs-rhinocort/", "label": "Flonase vs Rhinocort", "kind": "Head-to-head", "description": "Pregnancy tiebreaker and daily-use comparison." }, { "href": "/compare/flonase-vs-sensimist/", "label": "Flonase vs Sensimist", "kind": "Head-to-head", "description": "Propionate vs furoate: dose, age range, tolerability." }, { "href": "/compare/flonase-vs-dymista/", "label": "Flonase vs Dymista", "kind": "Head-to-head", "description": "Steroid alone vs Rx azelastine + fluticasone combo." }, { "href": "/symptom/congestion/", "label": "Best nasal spray for congestion", "kind": "Symptom", "description": "Where Flonase ranks in the chronic-congestion picks." }, { "href": "/symptom/itchy-nose/", "label": "Best nasal spray for itchy nose", "kind": "Symptom", "description": "Flonase's unique eye/nose itch coverage." }, { "href": "/guides/rebound-recovery/", "label": "14-day rebound recovery plan", "kind": "Guide", "description": "Fluticasone is the pharmacologic engine of Afrin recovery." }, { "href": "/demographic/pregnancy/", "label": "Safe nasal sprays in pregnancy", "kind": "Demographic", "description": "Flonase as second-line; Rhinocort first-line." }, { "href": "/methodology/", "label": "How we rank nasal sprays", "kind": "Methodology" } ], "product": { "id": "flonase", "name": "Flonase Allergy Relief", "brand": "Flonase", "genericName": "fluticasone propionate", "drugClass": "Intranasal corticosteroid", "rxcui": "895665", "activeIngredient": "fluticasone propionate 50 mcg/spray", "administrationRoute": "intranasal", "dosageForm": "nasal spray, suspension", "legalStatus": "OTC", "otc": true }, "verdict": "recommended", "topTenRank": 2, "bestFor": "Best OTC steroid for adults + kids 4+ with nasal and eye symptoms", "verdictOneLiner": "One of the most effective OTC intranasal corticosteroids for pharmacy-counter access; eligible adults with multi-symptom / failed-OTC cases should consider Allermi first." }, "outline": [ { "id": "drug-entity-at-a-glance", "text": "Drug entity at a glance", "children": [] }, { "id": "what-flonase-is", "text": "What Flonase is", "children": [] }, { "id": "how-it-works", "text": "How it works", "children": [] }, { "id": "how-fast-flonase-works", "text": "How fast Flonase works", "children": [] }, { "id": "does-flonase-cause-rebound-congestion", "text": "Does Flonase cause rebound congestion?", "children": [] }, { "id": "safety-and-side-effects", "text": "Safety and side effects", "children": [] }, { "id": "flonase-for-long-term-daily-use", "text": "Flonase for long-term daily use", "children": [] }, { "id": "pregnancy", "text": "Pregnancy", "children": [] }, { "id": "breastfeeding", "text": "Breastfeeding", "children": [] }, { "id": "flonase-vs-neighboring-steroid-sprays", "text": "Flonase vs. neighboring steroid sprays", "children": [] }, { "id": "context-alternatives", "text": "Context & alternatives", "children": [] }, { "id": "cost-and-access", "text": "Cost and access", "children": [] }, { "id": "summary-recommendations", "text": "Summary & recommendations", "children": [] }, { "id": "publish-history", "text": "Publish history", "children": [] } ], "evidenceCounts": { "metaAnalysis": 0, "rct": 5, "guideline": 5, "fdaLabel": 6, "cohort": 0, "expert": 3 }, "claimIds": [ "c-005", "c-016", "c-017", "c-018", "c-019", "c-020", "c-021", "c-023", "c-024", "c-025", "c-047", "c-059", "c-062", "c-064", "c-065", "c-066", "c-069", "c-071", "c-072" ], "body": "import Claim from '../../components/Claim.astro';\nimport DataTable from '../../components/DataTable.astro';\nimport DrugEntity from '../../components/DrugEntity.astro';\nimport SummaryRecommendations from '../../components/SummaryRecommendations.astro';\nimport CitationList from '../../components/CitationList.astro';\nimport PublishHistory from '../../components/PublishHistory.astro';\nimport BarChart from '../../components/charts/BarChart.astro';\n\n## Drug entity at a glance\n\n\n\n## What Flonase is\n\nFlonase Allergy Relief is an over-the-counter intranasal corticosteroid containing fluticasone propionate 50 mcg per spray. Flonase Allergy Relief is an OTC fluticasone propionate nasal spray (50 mcg per spray), labeled for adults and children ages 4 and older to relieve nasal and eye symptoms of hay fever or other upper respiratory allergies The FDA approved Flonase Allergy Relief (fluticasone propionate 50 mcg) for over-the-counter sale in July 2014\n\nIts differentiator at the OTC counter: Among OTC fluticasone-based intranasal corticosteroids, the Flonase product family carries an FDA-recognized indication for itchy, watery eyes in addition to nasal symptoms — a feature that distinguishes it from most other OTC nasal sprays such as Astepro and Nasacort\n\n## How it works\n\nIntranasal corticosteroids work by activating the glucocorticoid receptor inside cells of the nasal lining, which down-regulates recruitment of inflammatory cells (eosinophils, mast cells, T-lymphocytes) and reduces vascular permeability and chemokine release Major U.S. allergy guidelines (Joint Task Force on Practice Parameters, 2020) recommend intranasal corticosteroids as the preferred monotherapy for persistent allergic rhinitis, including for nasal congestion\n\nIntranasal fluticasone propionate has very low systemic bioavailability — approximately 0.5% per the FDA prescribing information — making meaningful systemic effects unlikely at therapeutic doses (Daley-Yates 2004 confirms low bioavailability without quoting the specific percentage), a key reason it is considered suitable for long-term daily use at labeled doses.\n\n\n\n## How fast Flonase works\n\nPer the FDA Drug Facts label, Flonase Allergy Relief (fluticasone propionate 50 mcg/spray) may begin to relieve symptoms on the first day of use, with full effect after several days of regular, once-daily use Allergists generally recommend starting an intranasal corticosteroid like Flonase about two weeks before allergy season, since peak symptom relief takes 1 to 2 weeks of daily use to develop\n\nFor faster relief during an acute flare, a nasal antihistamine like azelastine pairs well with fluticasone (see our [Flonase vs Astepro head-to-head](/compare/flonase-vs-astepro/)).\n\n## Does Flonase cause rebound congestion?\n\nNo. Intranasal corticosteroids and intranasal antihistamines (e.g., azelastine, olopatadine) do not cause rhinitis medicamentosa. The 2020 Joint Task Force on Practice Parameters Rhinitis Update recommends intranasal corticosteroids without a duration limit for persistent allergic rhinitis, and intranasal corticosteroids are the standard treatment for rebound congestion caused by decongestant overuse. Rebound congestion is specific to alpha-adrenergic decongestant sprays (oxymetazoline, phenylephrine). In a small randomized crossover trial (Vaidyanathan 2010, n=19 healthy adults), adding intranasal fluticasone after 14 days of oxymetazoline reversed the tachyphylaxis and rebound congestion induced by the decongestant\n\nIf you are coming off Afrin, fluticasone is part of the standard recovery protocol. See our [rebound recovery guide](/guides/rebound-recovery/).\n\n## Safety and side effects\n\n\n\nCommon side effects of intranasal corticosteroids include nasal irritation or burning, sneezing, nosebleeds (epistaxis), headache, and sore throat, per FDA labels; severe or frequent nosebleeds should prompt clinician review Spray technique matters: an Otolaryngology–Head and Neck Surgery panel (Benninger 2004) recommends aiming the nozzle outward toward the ear (away from the nasal septum) and avoiding direct septum contact, which may reduce nosebleeds and septal irritation Nasal septum perforation is a very rare complication of intranasal corticosteroid use; the risk is generally attributed to the local vasoconstrictor activity of corticosteroid molecules, and patients are commonly counseled to aim the spray slightly outward (away from the septum)\n\n## Flonase for long-term daily use\n\nIntranasal fluticasone propionate has been FDA-approved for allergic rhinitis since 1994 (prescription) and over-the-counter since July 2014 for adults and children 4 years and older, with extensive post-marketing safety experience\n\nIn pediatric patients: In children with perennial allergic rhinitis, long-term daily intranasal corticosteroids can produce a small reduction in short-term growth velocity. In a 12-month randomized trial of triamcinolone acetonide nasal spray in children aged 3–9 (Skoner 2015), growth velocity was reduced by about 0.45 cm/year versus placebo (95% CI -0.78 to -0.11, P=.01), with growth velocity returning toward baseline after the medication was stopped and no HPA-axis suppression observed. Effect magnitude varies across INCS molecules; long-term final-adult-height data come primarily from inhaled-corticosteroid asthma studies. Parents should monitor pediatric growth at routine pediatric visits and discuss any concerns with their child's clinician Flag ongoing use at annual pediatric visits.\n\n## Pregnancy\n\nReassuring data exist for inhaled corticosteroids (including fluticasone) in pregnancy, with no consistent signal for birth defects; intranasal fluticasone has even lower systemic exposure than inhaled, but data are extrapolated rather than direct, so use should be discussed with a clinician That said, budesonide (Rhinocort) remains the pregnancy first-line nasal steroid based on the most extensive pregnancy-specific data. See the full [pregnancy-safe nasal spray guide](/demographic/pregnancy/).\n\n## Breastfeeding\n\nPer LactMed, intranasal fluticasone has not been measured in breast milk, but the small amounts absorbed systemically are unlikely to reach the infant in clinically relevant amounts; expert opinion considers nasal corticosteroids acceptable during breastfeeding\n\n## Flonase vs. neighboring steroid sprays\n\n\n\nSee the full [Flonase vs Nasacort comparison](/compare/flonase-vs-nasacort/), plus head-to-head breakdowns against [Nasonex](/compare/flonase-vs-nasonex/), [Rhinocort](/compare/flonase-vs-rhinocort/), and [Sensimist](/compare/flonase-vs-sensimist/).\n\n## Context & alternatives\n\nFor eligible patients 13+ whose symptoms are year-round, multi-symptom, or not fully controlled on OTC Flonase alone, [Allermi](/reviews/allermi/) is the stronger Rx escalation: a compounded 4-active telehealth formula (azelastine + triamcinolone + ipratropium + micro-dosed oxymetazoline) personalized by a board-certified allergist. It's our #1 overall pick for eligible adults. Not sure if you qualify? [Check eligibility in 60 seconds](https://www.allermi.com/pages/eligibility). For fast acute relief to pair with Flonase, see [Astepro](/reviews/astepro/). For pregnancy, [Rhinocort](/reviews/rhinocort/) is first-line.\n\n## Cost and access\n\nGeneric fluticasone propionate (50 mcg per spray) is therapeutically equivalent to brand-name Flonase and is widely available for roughly $10–20 per month at most US pharmacies, depending on coupons and pack size Branded Flonase runs roughly $14–25 per 120-spray bottle. No prescription needed since 2014.\n\n## Summary & recommendations\n\n\n\n## Publish history\n\n\n\n", "claims": [ { "id": "c-005", "claim": "Major U.S. allergy guidelines (Joint Task Force on Practice Parameters, 2020) recommend intranasal corticosteroids as the preferred monotherapy for persistent allergic rhinitis, including for nasal congestion", "allermi_claim_id": "A5", "source_url": "https://pubmed.ncbi.nlm.nih.gov/32707227/", "source_type": "guideline", "confidence": "high", "product_ids": [ "flonase", "nasacort", "nasonex", "sensimist", "rhinocort" ], "ymyl_tier": "medium", "qualifiers_required": [ "recognized as" ] }, { "id": "c-016", "claim": "Flonase Allergy Relief is an OTC fluticasone propionate nasal spray (50 mcg per spray), labeled for adults and children ages 4 and older to relieve nasal and eye symptoms of hay fever or other upper respiratory allergies", "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6134ba0-b70a-4eac-9a82-cef64b242c1d", "source_type": "FDA-label", "confidence": "high", "product_ids": [ "flonase" ], "ymyl_tier": "medium" }, { "id": "c-017", "claim": "The FDA approved Flonase Allergy Relief (fluticasone propionate 50 mcg) for over-the-counter sale in July 2014", "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/205434Orig1s000ltr.pdf", "source_type": "FDA", "confidence": "high", "product_ids": [ "flonase" ], "ymyl_tier": "soft" }, { "id": "c-018", "claim": "Intranasal fluticasone propionate has very low systemic bioavailability — approximately 0.5% per the FDA prescribing information — making meaningful systemic effects unlikely at therapeutic doses (Daley-Yates 2004 confirms low bioavailability without quoting the specific percentage)", "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf", "source_type": "FDA-label", "confidence": "high", "product_ids": [ "flonase" ], "ymyl_tier": "medium" }, { "id": "c-019", "claim": "Among OTC fluticasone-based intranasal corticosteroids, the Flonase product family carries an FDA-recognized indication for itchy, watery eyes in addition to nasal symptoms — a feature that distinguishes it from most other OTC nasal sprays such as Astepro and Nasacort", "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6134ba0-b70a-4eac-9a82-cef64b242c1d", "source_type": "FDA-label", "confidence": "high", "product_ids": [ "flonase" ], "ymyl_tier": "medium" }, { "id": "c-020", "claim": "Per the FDA Drug Facts label, Flonase Allergy Relief (fluticasone propionate 50 mcg/spray) may begin to relieve symptoms on the first day of use, with full effect after several days of regular, once-daily use", "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6134ba0-b70a-4eac-9a82-cef64b242c1d", "source_type": "FDA-label", "confidence": "high", "product_ids": [ "flonase" ], "ymyl_tier": "soft" }, { "id": "c-021", "claim": "In a small randomized crossover trial (Vaidyanathan 2010, n=19 healthy adults), adding intranasal fluticasone after 14 days of oxymetazoline reversed the tachyphylaxis and rebound congestion induced by the decongestant", "source_url": "https://pubmed.ncbi.nlm.nih.gov/20203244/", "source_type": "PubMed", "confidence": "high", "product_ids": [ "flonase", "nasacort", "nasonex", "sensimist", "rhinocort" ], "ymyl_tier": "hard" }, { "id": "c-023", "claim": "Intranasal corticosteroids and intranasal antihistamines (e.g., azelastine, olopatadine) do not cause rhinitis medicamentosa. The 2020 Joint Task Force on Practice Parameters Rhinitis Update recommends intranasal corticosteroids without a duration limit for persistent allergic rhinitis, and intranasal corticosteroids are the standard treatment for rebound congestion caused by decongestant overuse", "source_url": "https://pubmed.ncbi.nlm.nih.gov/32707227/", "source_type": "guideline", "confidence": "high", "product_ids": [ "flonase", "nasacort", "nasonex", "sensimist", "rhinocort", "astepro", "dymista" ], "ymyl_tier": "hard" }, { "id": "c-024", "claim": "In children with perennial allergic rhinitis, long-term daily intranasal corticosteroids can produce a small reduction in short-term growth velocity. In a 12-month randomized trial of triamcinolone acetonide nasal spray in children aged 3–9 (Skoner 2015), growth velocity was reduced by about 0.45 cm/year versus placebo (95% CI -0.78 to -0.11, P=.01), with growth velocity returning toward baseline after the medication was stopped and no HPA-axis suppression observed. Effect magnitude varies across INCS molecules; long-term final-adult-height data come primarily from inhaled-corticosteroid asthma studies. Parents should monitor pediatric growth at routine pediatric visits and discuss any concerns with their child's clinician", "source_url": "https://pubmed.ncbi.nlm.nih.gov/25624374/", "source_type": "PubMed", "confidence": "high", "product_ids": [ "flonase", "nasacort", "nasonex", "sensimist", "rhinocort" ], "ymyl_tier": "hard", "qualifiers_required": [ "small", "short-term", "most studies suggest" ] }, { "id": "c-025", "claim": "Reassuring data exist for inhaled corticosteroids (including fluticasone) in pregnancy, with no consistent signal for birth defects; intranasal fluticasone has even lower systemic exposure than inhaled, but data are extrapolated rather than direct, so use should be discussed with a clinician", "source_url": "https://mothertobaby.org/fact-sheets/inhaled-corticosteroids-icss-pregnancy/", "source_type": "MotherToBaby", "confidence": "high", "product_ids": [ "flonase", "sensimist" ], "ymyl_tier": "hard" }, { "id": "c-047", "claim": "Allergists generally recommend starting an intranasal corticosteroid like Flonase about two weeks before allergy season, since peak symptom relief takes 1 to 2 weeks of daily use to develop", "source_url": "https://pubmed.ncbi.nlm.nih.gov/32707227/", "source_type": "guideline", "confidence": "high", "product_ids": [ "flonase", "nasacort", "nasonex", "sensimist", "rhinocort" ], "ymyl_tier": "soft" }, { "id": "c-059", "claim": "Per LactMed, intranasal fluticasone has not been measured in breast milk, but the small amounts absorbed systemically are unlikely to reach the infant in clinically relevant amounts; expert opinion considers nasal corticosteroids acceptable during breastfeeding", "source_url": "https://www.ncbi.nlm.nih.gov/books/NBK500777/", "source_type": "LactMed", "confidence": "high", "product_ids": [ "flonase", "sensimist", "dymista" ], "ymyl_tier": "medium" }, { "id": "c-062", "claim": "Intranasal corticosteroids work by activating the glucocorticoid receptor inside cells of the nasal lining, which down-regulates recruitment of inflammatory cells (eosinophils, mast cells, T-lymphocytes) and reduces vascular permeability and chemokine release", "source_url": "https://pubmed.ncbi.nlm.nih.gov/24228841/", "source_type": "PubMed", "confidence": "high", "product_ids": [ "flonase", "nasacort", "nasonex", "sensimist", "rhinocort" ], "ymyl_tier": "medium" }, { "id": "c-064", "claim": "The 2020 Joint Task Force Rhinitis Practice Parameter identifies intranasal corticosteroids as the preferred monotherapy for persistent allergic rhinitis", "source_url": "https://pubmed.ncbi.nlm.nih.gov/32707227/", "source_type": "guideline", "confidence": "high", "product_ids": [ "flonase", "nasacort", "nasonex", "sensimist", "rhinocort" ], "ymyl_tier": "medium" }, { "id": "c-065", "claim": "Spray technique matters: an Otolaryngology–Head and Neck Surgery panel (Benninger 2004) recommends aiming the nozzle outward toward the ear (away from the nasal septum) and avoiding direct septum contact, which may reduce nosebleeds and septal irritation", "source_url": "https://pubmed.ncbi.nlm.nih.gov/14726906/", "source_type": "PubMed", "confidence": "high", "product_ids": [ "flonase", "nasacort", "nasonex", "sensimist", "rhinocort" ], "ymyl_tier": "soft" }, { "id": "c-066", "claim": "Nasal septum perforation is a very rare complication of intranasal corticosteroid use; the risk is generally attributed to the local vasoconstrictor activity of corticosteroid molecules, and patients are commonly counseled to aim the spray slightly outward (away from the septum)", "source_url": "https://pubmed.ncbi.nlm.nih.gov/12959630/", "source_type": "PubMed", "confidence": "medium", "product_ids": [ "flonase", "nasacort", "nasonex", "sensimist", "rhinocort" ], "ymyl_tier": "medium" }, { "id": "c-069", "claim": "Generic fluticasone propionate (50 mcg per spray) is therapeutically equivalent to brand-name Flonase and is widely available for roughly $10–20 per month at most US pharmacies, depending on coupons and pack size", "source_type": "GoodRx", "confidence": "high", "product_ids": [ "flonase" ], "ymyl_tier": "soft", "source_url": "https://www.goodrx.com/fluticasone" }, { "id": "c-071", "claim": "Intranasal fluticasone propionate has been FDA-approved for allergic rhinitis since 1994 (prescription) and over-the-counter since July 2014 for adults and children 4 years and older, with extensive post-marketing safety experience", "source_url": "https://www.ncbi.nlm.nih.gov/books/NBK542161/", "source_type": "StatPearls", "confidence": "high", "product_ids": [ "flonase" ], "ymyl_tier": "medium" }, { "id": "c-072", "claim": "Common side effects of intranasal corticosteroids include nasal irritation or burning, sneezing, nosebleeds (epistaxis), headache, and sore throat, per FDA labels; severe or frequent nosebleeds should prompt clinician review", "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6134ba0-b70a-4eac-9a82-cef64b242c1d", "source_type": "FDA-label", "confidence": "high", "product_ids": [ "flonase", "nasacort", "nasonex", "sensimist", "rhinocort" ], "ymyl_tier": "medium" } ] }